Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
The H1N1 (swine flu) virus appears to be spreading eastward across Europe and Asia, after appearing to have leveled off in the U.S. and some western European countries, the WHO said Friday, Reuters reports.
Reuters: "The pandemic of swine flu may be hitting a peak in the United States, health experts said on Friday. But they stressed that influenza, especially a pandemic, could hit several peaks in a single season. They said weeks or months more of disease could be expected.
NanoViricides, Inc., announced today that Dr. Eugene Seymour, MD MPH, CEO of the Company, presented lifetime data from the recent FluCide™ animal study on November 19th at the Influenza Congress USA 2009 in Washington, DC (www.terrapinn.com/usaflu). These data clearly established that the new version of FluCide™ is superior to the older version.
At its annual fall meeting, the Ontario Medical Association (OMA) recognized front line health care workers for their hard work and dedication to patient during this unprecedented flu season. The OMA Council, which represents doctors from across the province, overwhelmingly passed a motion to express its thanks to Medical Officers of Health, physicians, nurses, and other health care professionals for their leadership.
Influenza, particularly H1N1, has understandably captured the attention of public health officials, the media and the public. However, an analysis from Children's Hospital Boston, based on patients seen in its emergency department (ED) during several recent flu seasons, shows that another virus - respiratory syncytial virus (RSV) - takes a substantially greater disease toll among young children than does seasonal flu.
The Department of Health today began providing free H1N1 flu shots to members of priority groups that did not have previous access to the vaccine.
For the protection of frontline health care and emergency medical workers at high risk of infection, the U.S. Department of Labor's Occupational Safety and Health Administration (OSHA) today issued a compliance directive to ensure uniform procedures when conducting inspections to identify and minimize or eliminate high to very high risk occupational exposures to the 2009 H1N1 influenza A virus.
Rates of infection by the 2009 H1N1 influenza virus may have peaked in late October, but the pandemic flu virus continues to be a potential source of illness in all age groups, including the elderly, according to a new report by Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services.
The deaths of 41 people from six countries who had received the H1N1 (swine flu) vaccine were not directly linked to the vaccine, the WHO said Thursday, the Associated Press/MSNBC reports (11/19).
Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that a combination of its synthetic consensus H1N1, H2N2, H3N2, and H5N1 influenza vaccine candidates achieved protective antibody responses against several different influenza sub-types and strains in ferrets.
Immunization with either live attenuated influenza vaccine (LAIV, also known as FluMist®), or trivalent inactivated influenza vaccine (TIV), appears to offer a protection (~ 45%) against the novel A/H1N1 virus, the cause of the present influenza pandemic. However, the benefit was largely attributed to the youngest age group. The finding emerges from an evaluation of medical encounters and seasonal influenza immunization of U.S. military service members.
On November 19, 2009, the kick-off meeting for the Euregio-project "EurSafety Health-net" has taken place. EurSafety Health-net is the follow-up of EUREGIO MRSA-net, that, according to the Robert Koch Institute, gained some sort of model character all over the nation when talking about prevention of hospital acquired MRSA infection. Besides the protection against infection, the main goal of this new project is to strengthen the patients' safety on both sides of the border.
Washington State Nurses Association (WSNA), representing more than 1,600 registered nurses at Sacred Heart Medical Center, is holding a press conference today to highlight serious concerns about the safety of nurses and patients at Sacred Heart Medical Center during this H1N1 pandemic.
A commentary in the December issue of The Lancet Infectious Diseases brings to light the gaps in knowledge on the transmission of a common pathogen - the influenza virus - and its impact on decisions about how best to protect health care workers. Infectious diseases specialist Leonard Mermel, DO, medical director of infection control for Rhode Island Hospital, looks at the ongoing debate in light of the H1N1 pandemic, what past research tells us about the spread of influenza, and what is missing in the debate. His commentary is currently available in an online first edition.
Case Western Reserve University (CWRU) School of Medicine (SOM) has received a Robert Wood Johnson grant to fund a Public Health Practice Based Research Network called The Ohio Research Association for Public Health Improvement (RAPHI).
A new study on pediatric H1N1 influenza admissions has found that asthma is a significant risk factor for severe disease in children with pandemic H1N1 compared with the seasonal flu.
Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has expanded its Phase 2 clinical study of a proprietary investigational triple-combination antiviral drug therapy for influenza to include centers in the United States, Canada and Europe. The study, which was initiated in August 2009 in the Southern Hemisphere, is designed to investigate Adamas' triple combination antiviral drug (TCAD) therapy as a treatment for influenza A, including novel influenza A/H1N1, the cause of the current flu pandemic.
SinoFresh Healthcare Products, Inc. announced today the successful results of its initial pilot animal study testing the efficacy of the SinoFresh Nasal Spray product when used on animals infected with the H1N1 virus. The study data suggests that treatment with SinoFresh allowed the infected animals to recover more rapidly from H1N1 infection than did untreated animals. In addition, pre-treatment with SinoFresh Nasal Spray decreased the severity and/or incidence of infection.
Public health officials walking a tightrope between massive demand for vaccines and intense public scrutiny of side effects now have a new standard for evaluating the safety of their vaccination programs.
Researchers at Yale School of Medicine have found that exaggerated responses of the immune system explain why the elderly succumb to viral infections more readily than younger people. Published in the November 19 Cell Host & Microbe, the study bucks the general belief that declining immune responses are to blame for susceptibility to viral infections.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.